Dupilumab for atopic dermatitis: evidence to date

杜皮鲁玛 特应性皮炎 医学 湿疹面积及严重程度指数 不利影响 皮肤病科 临床试验 安慰剂 内科学 病理 替代医学
作者
Maria Alexandra Rodrigues,Miguel Nogueira,Tiago Ribeiro Torres
出处
期刊:Giornale italiano di dermatologia e venereologia [Edizioni Minerva Medica]
卷期号:154 (6): 696-713 被引量:22
标识
DOI:10.23736/s0392-0488.19.06417-4
摘要

INTRODUCTION: Atopic dermatitis (AD) is a common chronic, pruritic inflammatory dermatosis. The inflammatory response is characterized by a T helper 2 (Th2) immune response phenotype. EVIDENCE ACQUISITION: To assess current available data on dupilumab, the writers of this article did a comprehensive search in different databases, including Medline, EMBASE, SCOPUS, and clinical trial registries. All relevant articles identified were then manually reviewed. Information regarding dupilumab mechanism of action, pharmacokinetics, clinical efficacy, safety, and future trends was then summarized. EVIDENCE SYNTHESIS: Topical therapy is the main treatment in mild-to-moderate AD, but many cases of moderate-to-severe require systemic treatments. Dupilumab is the first biologic approved for the treatment of adults with moderate-to-severe AD. It inhibits IL-4 and IL-13 signaling pathways and reduces Th2 response. Clinical trials have demonstrated significantly improved clinical and patient-reported outcomes. The addition of application of topical corticosteroids results in a more significant improvement in signs and symptoms of AD than with use of dupilumab in monotherapy. The vast majority of patients improves under dupilumab, and almost 40% of patients achieve clear or nearly clear skin. In addition to its effectiveness, dupilumab also has a favorable safety profile. Frequent adverse events reported in the clinical trials were mostly mild-to-moderate and included nasopharyngitis, upper respiratory tract infection, injection site reactions, and conjunctivitis. CONCLUSIONS: In general, rates of adverse events occurred with similar frequency between the treatment and placebo groups. Conjunctivitis seems to be a dupilumab-specific side effect and so far has only been observed in atopic dermatitis patients (not in asthma or nasal polyposis). There were no major serious safety concerns identified in phase III clinical trials. Trials in the pediatric population are ongoing and are highly awaited.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凡空发布了新的文献求助10
1秒前
1秒前
2秒前
cc发布了新的文献求助10
3秒前
CipherSage的应助被xinxin采纳,获得10
4秒前
4秒前
4秒前
地动完成签到 ,获得积分10
4秒前
科研通AI6.2的应助被wangfei采纳,获得30
4秒前
long发布了新的文献求助10
5秒前
小羊发布了新的文献求助10
5秒前
5秒前
JamesPei的应助被楠楠采纳,获得10
5秒前
乐观碧彤发布了新的文献求助10
5秒前
6秒前
迷人雪卉完成签到,获得积分10
6秒前
李麟发布了新的文献求助10
7秒前
7秒前
7秒前
空集发布了新的文献求助10
7秒前
7秒前
8秒前
笔落惊风雨完成签到,获得积分10
8秒前
烨采发布了新的文献求助10
8秒前
8秒前
FashionBoy的应助被孤独口红采纳,获得30
9秒前
英俊的铭的应助被别晚睡采纳,获得10
9秒前
9秒前
9秒前
Lucas的应助被张长弓采纳,获得10
9秒前
9秒前
9秒前
抽烟酒牲发布了新的文献求助30
11秒前
11秒前
NexusExplorer的应助被lkh采纳,获得10
11秒前
ws123发布了新的文献求助10
12秒前
秀丽人杰完成签到,获得积分10
13秒前
dididi发布了新的文献求助10
13秒前
王添赟发布了新的文献求助10
13秒前
汉堡包的应助被Wdw2236采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188088
求助须知:如何正确求助?哪些是违规求助? 9575942
关于积分的说明 21844291
捐赠科研通 7785857
什么是DOI,文献DOI怎么找? 3435158
关于科研通互助平台的介绍 2559529
邀请新用户注册赠送积分活动 2482065